Clinical Trial Update: Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL) [Phase 3]

View source ↗

Summary

Phase 3 PEARL trial update for Lasofoxifene in osteoporosis shows the study status as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Lasofoxifene (Lasofoxifene)

Snippet

Sponsor: Ligand Pharmaceuticals | Conditions: Osteoporosis | Phase 3 | Status: COMPLETED